iZafe Group AB (publ) (IZAFE-B.ST)
SEK 0.21
(-0.93%)
SEK 0.21
(-0.93%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -15.61 Million SEK | 25.38% |
| 2022 | -21.93 Million SEK | 33.02% |
| 2021 | -32.35 Million SEK | -37.09% |
| 2020 | -10.67 Million SEK | -27.47% |
| 2019 | -20.75 Million SEK | -59.97% |
| 2018 | -10.16 Million SEK | -166.2% |
| 2017 | -3.82 Million SEK | 23.77% |
| 2016 | -5.06 Million SEK | -835.55% |
| 2015 | -535.64 Thousand SEK | 52.13% |
| 2014 | -1.11 Million SEK | 33.02% |
| 2013 | -1.67 Million SEK | 6.2% |
| 2012 | -1.78 Million SEK | 45.79% |
| 2011 | -3.28 Million SEK | 22.97% |
| 2010 | -4.26 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -3.88 Million SEK | -4.59% |
| 2024 Q1 | -4.58 Million SEK | -39.03% |
| 2024 Q2 | -3.02 Million SEK | 34.02% |
| 2023 Q1 | -2.96 Million SEK | 31.24% |
| 2023 Q3 | -3.15 Million SEK | -0.77% |
| 2023 Q2 | -3.13 Million SEK | -5.59% |
| 2023 Q4 | -3.75 Million SEK | -18.84% |
| 2023 FY | - SEK | 25.38% |
| 2022 Q2 | -4.09 Million SEK | 30.95% |
| 2022 FY | - SEK | 33.02% |
| 2022 Q3 | -4.69 Million SEK | -14.42% |
| 2022 Q1 | -5.93 Million SEK | 48.53% |
| 2022 Q4 | -4.31 Million SEK | 7.93% |
| 2021 Q2 | -6.52 Million SEK | -5.97% |
| 2021 Q4 | -11.53 Million SEK | -168.44% |
| 2021 Q1 | -6.16 Million SEK | -195.91% |
| 2021 FY | - SEK | -37.09% |
| 2021 Q3 | -4.29 Million SEK | 34.19% |
| 2020 Q2 | -4.36 Million SEK | -21.63% |
| 2020 Q1 | -3.58 Million SEK | 33.96% |
| 2020 Q4 | 6.42 Million SEK | 223.12% |
| 2020 FY | - SEK | -27.47% |
| 2020 Q3 | -5.21 Million SEK | -19.55% |
| 2019 Q2 | -4.84 Million SEK | -25.65% |
| 2019 FY | - SEK | -59.97% |
| 2019 Q3 | -2.7 Million SEK | 44.24% |
| 2019 Q4 | -5.43 Million SEK | -101.15% |
| 2019 Q1 | -3.85 Million SEK | -107.82% |
| 2018 Q2 | -3.87 Million SEK | -47.36% |
| 2018 FY | - SEK | -166.2% |
| 2018 Q1 | -2.62 Million SEK | -50.54% |
| 2018 Q3 | -1.81 Million SEK | 53.25% |
| 2018 Q4 | -1.85 Million SEK | -2.43% |
| 2017 Q2 | -695 Thousand SEK | -78.84% |
| 2017 Q3 | -990.08 Thousand SEK | -42.46% |
| 2017 Q4 | -1.74 Million SEK | -76.39% |
| 2017 FY | - SEK | 23.77% |
| 2017 Q1 | -388.62 Thousand SEK | -263.39% |
| 2016 Q3 | -632.8 Thousand SEK | 85.75% |
| 2016 FY | - SEK | -835.55% |
| 2016 Q2 | -4.44 Million SEK | -2434.69% |
| 2016 Q1 | -175.19 Thousand SEK | -27.63% |
| 2016 Q4 | 237.84 Thousand SEK | 137.59% |
| 2015 Q4 | -137.27 Thousand SEK | 0.0% |
| 2015 Q2 | -130.54 Thousand SEK | 0.0% |
| 2015 Q1 | -130.54 Thousand SEK | 69.8% |
| 2015 FY | - SEK | 52.13% |
| 2015 Q3 | -137.27 Thousand SEK | -5.16% |
| 2014 FY | - SEK | 33.02% |
| 2014 Q4 | -432.22 Thousand SEK | -105.75% |
| 2014 Q2 | -210.42 Thousand SEK | 20.94% |
| 2014 Q1 | -266.17 Thousand SEK | 59.25% |
| 2014 Q3 | -210.07 Thousand SEK | 0.17% |
| 2013 Q3 | -309.9 Thousand SEK | 32.63% |
| 2013 FY | - SEK | 6.2% |
| 2013 Q4 | -653.19 Thousand SEK | -110.77% |
| 2013 Q1 | -247.28 Thousand SEK | 54.06% |
| 2013 Q2 | -460.02 Thousand SEK | -86.03% |
| 2012 Q2 | -441.2 Thousand SEK | -11.52% |
| 2012 FY | - SEK | 45.79% |
| 2012 Q1 | -395.61 Thousand SEK | 0.0% |
| 2012 Q4 | -538.3 Thousand SEK | -32.71% |
| 2012 Q3 | -405.6 Thousand SEK | 8.07% |
| 2011 FY | - SEK | 22.97% |
| 2010 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AddLife AB (publ) | 1.54 Billion SEK | 101.01% |
| Biotage AB (publ) | 432 Million SEK | 103.615% |
| Bonesupport Holding AB (publ) | 28.93 Million SEK | 153.969% |
| Doxa AB (publ) | 296 Million SEK | 105.276% |
| Elekta AB (publ) | 3.29 Billion SEK | 100.475% |
| Ortivus AB (publ) | -14.92 Million SEK | -4.63% |
| Ortivus AB (publ) | -14.92 Million SEK | -4.63% |
| Q-linea AB (publ) | -210.98 Million SEK | 92.598% |
| S2Medical AB (publ) | -13.52 Million SEK | -15.432% |
| Synsam AB (publ) | 1.71 Billion SEK | 100.913% |